← Kiniksa Pharmaceuticals International, plc (KNSA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kiniksa Pharmaceuticals International, plc (KNSA)
Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Kiniksa Pharmaceuticals International (KNSA) is a ~$1.1B market-cap specialty pharma with 315 employees, anchored by a commercial-stage pericarditis franchise (Rilonacept) and a Phase 3 pipeline led by KPL-387 in pericarditis. The company turned profitable in 2025 on $678M revenue after years of losses, and carries $190M net cash with no disclosed debt.
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KPL-387 | Phase 3 | Pericarditis |
| mavrilimumab | Phase 3 | COVID |
| KPL-404 | Phase 2 | Arthritis, Rheumatoid |
| Rilonacept | Phase 3 | Recurrent Pericarditis |
| KPL-914 | Phase 2 | Recurrent Pericarditis |
| Vixarelimab | Phase 2 | Prurigo Nodularis |
| KPL-716 | Phase 2 | Chronic Idiopathic Urticaria |
| prednisone | Phase 2 | Giant Cell Arteritis |
Price & technical context
3-month
+16.6%
6-month
+56.3%
12-month
+93.7%
52-wk range
$37.01–$80.92
vs 50-day MA
-2.0%
vs 200-day MA
+34.2%
Realized vol
47.1%
Max drawdown
-34.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KNSA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.